BioCentury
ARTICLE | Clinical News

Tenecteplase: Phase II data

March 9, 2015 7:00 AM UTC

Researchers at the University of Glasgow reported data from the open-label, U.K. Phase II ATTEST trial in 104 patients with supratentorial ischemic stroke showing that there was no significant difference between IV tenecteplase and IV alteplase on the primary endpoint of the percentage of penumbra salvaged at 24-48 hours (68% for both, p=0.81). Additionally, there was no significant difference between tenecteplase and alteplase in the incidence of symptomatic intracerebral hemorrhage (2% vs. 4%, p=0.55 by SITS-MOST definition and 6% vs. 8%, p=0.59 by ECASS II definition) or total intracerebral hemorrhage events (15% vs. 29%, p=0.091). There was no difference in the incidence of serious adverse events between treatment groups. Patients received 0.25 mg/kg tenecteplase or 0.9 mg/kg alteplase within 4-5 hours of onset of ischemic stroke. The Stroke Association funded the trial. Data were published in The Lancet Neurology. The researchers said they are planning to conduct a larger scale trial to further investigate the results. ...